Another previous study showed that western blot analysis was able to detect LATS1 in all normal liver tissues, whereas it was only detected in three out of seven HCC samples (9), which indicated that LATS1 loss may be involved in the development of liver cancer; therefore, a YAP-targeted therapy for liver cancer must focus on LATS1. This evidence concerns the gene YAP1 and liver cancer.